Concentrations of endogenous cortisol were examined in 34 kidney-transplant recipients by improved 'high-performance" liquid chromatography. Ten recipients were treated with prednisolone and azathioprine, the others with prednisolone and cyclosporine. Peripheral serum samples were collected just before transplantation, daily for two weeks after the transplant, weekly until discharge for about two months, and then monthly or occasionally. Mean (± SD) cortisol concentrations, initially 145 ± 87 g/L, decreased immediately to 5.93 ± 5.11 tg/L after transplant, remained at almost these same values for two months, and then swiftly increased to 51 ± 59 jig/L by 1000 days. Cortisol concentrations within the period characterized by a cumulative dose of prednisolone at 300-700 mg were correlated significantly with the presence or absence of acute allograft rejection; patients with cortisol >4 1.9/L had a higher risk of rejection. The majority of stable patients showed cortisol concentrations between 1 and 4 g/L throughout the cumulative prednisolone period charactenzed above. Concentrations <1 zg/L after high-dose administration of methylprednisolone were accompanied by severe lung infection. We conclude that suppressed concentrations of endogenous cortisol, as assessed by highly specific HPLC, might provide a basis for predicting the therapeutic efficacy and adverse effects of prednisolone. 
5.93 ± 5.11 tg/L after transplant, remained at almost these same values for two months, and then swiftly increased to 51 ± 59 jig/L by 1000 days. Cortisol concentrations within the period characterized by a cumulative dose of prednisolone at 300-700 mg were correlated significantly with the presence or absence of acute allograft rejection; patients with cortisol >4 1.9/L had a higher risk of rejection. The majority of stable patients showed cortisol concentrations between 1 and 4 g/L throughout the cumulative prednisolone period charactenzed above. Concentrations <1 zg/L after high-dose administration of methylprednisolone were accompanied by severe lung infection. We conclude that suppressed concentrations of endogenous cortisol, as assessed by highly specific HPLC, might provide a basis for predicting the therapeutic efficacy and adverse effects of prednisolone.
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Renal transplantation has become the most effective therapeutic procedure for treating end-stage kidney disease (1) . Improvements in surgical techniques have shifted attention to the immunosuppressive care of patients after transplantation. Prednisolone (Pred) was previously considered the most important drug for this until cyclosporine (Cya) was found to give better results for graft surivival (2, 3) ; however, Fred continues to be used as a major immunosuppressant (4)3
The greatest challenge still facing clinicians is how to identify the patients at highest risk for developing graft rejection. Another problem is tapering the Pred dosage after a patient's condition has become stable. The pharmacodynamics of Fred have been studied in regard to (a) Fred-induced lymphocytopenia (5) (6) (7) (8) (9) , (b) the effects of Fred on mixed lymphocyte cultures (9) (10) (11) (12) (13) (14) , (c) the effects of Pred on mitogen-activated lymphocytes (15) (16) (17) , and cortisol (18) (19) (20) . Pre-operative mitogen-activated lymphocyte testing has recently been shown to successfully predict the pharmacodynaxnic effects of Fred on graft outcome (15) .
We have described in preliminary reports (21, 22 ) that concentrations of endogenous cortisol after transplantation are strongly correlated to rejection. This result is consistent with the results obtained from pre-operative mitogen-activated lymphocyte testing.
Here we present technical details of those studies with cortisol, conducted with "highperformance" liquid chromatography (HPLC).
Materials and Methods

Materials
Before the HPLC determination of endogenous cortisol, we pretreated samples with rapid-flow fractionation (RFF), having purchased the components of the RFF system from Kusano Scientific (Tokyo, Japan). The standardized apparatus has been described elsewhere (23) . In brief, the system consisted of two glass columns packed with diatomaceous earth granules (particle size 50-100 sm). The inner volume of the first column, 4 mL, retained 0.5 mL of sample; the second column, 0.8 mL inner volume, retained 50 pL of 50 g/L sodium hydroxide solution to eliminate acidic components in the extract. Extraction solvent, introduced in a reservoir glass tube, was delivered through the columns by nitrogen gas pressure at 1-2 kg/cm2. Using this system, we obtained an extract containing only neutral components in the plasma or serum specimen. Our HPLC system, a U-880 series obtained from Jasco (Tokyo, Japan), consisted of a reciprocal pump, an ultraviolet absorbance detector, and a chromatogram recorder. 
We also used a
Procedures
Extraction
procedure.
We added 5 pL of a standard ethanol solution containing 5 or 50 ng of dexamethasone to 0.5 mL of plasma or serum. The larger amount of internal standard was used for determining cortisol before transplant; the smaller, after transplant. To extract glucocorticoids by RFF, we used the procedure described previously (24) , with modifications in the extraction solvent mixture. When we used diethyl ether for the extraction, the glucocorticoids decomposedduring postextraction storage. Sometimes the very low concentrations of cortisol in the transplant patients were completely lost. These chemical reactions seemed to proceed under oxidative conditions caused by peroxide(s) in the diethyl ether, because when freshly distilled solvent or a solvent treated with reductive reagent such as sodium borohydride was used, no decomposition occurred and the glucocorticoids could be determined. In any case, the flow rate was 1.0 mL/min for solvent A and 2.0 mL/min for solvent B. The detector was set at 245 nm with an analytical sensitivity of maximum 0.001 A full-scale. The cortisol concentration was determined by comparison with a calibration curve made from the ratio of the peak-heights for cortisol standards (0.5-100 ng) to that for 5 ng or 50 ng of dexainethasone as the internal standard. Other chromatographic conditions were the same as described previously (23, 24) .
Patients
Medication.
The study included 34 kidney-transplant recipients, ages 19 to 53 years (mean ± SD: 33.3 ± 9.2), who underwent transplantation by conventional surgery. For immunosuppressive therapy, 10 patients were given prednisolone/azathioprine (PredlAza); the others, prednisolone/cyclosporine (Pred/Cya). The initial dose of Prod was 120 mg/day for Fred/Aza, 60 mg/day for PredlCya. The dose of Fred was gradually tapered over three months after transplant to 10-20 mg/day and then even more gradually thereafter. The Cya dose was varied according to its concentrations in plasma, the optimal considered to be between 50 and 150 mg/L at trough (25) . The Aza dose was determined by the usual therapeutic drug monitoring.
Diagnosis of acute rejection or rejection episode was based on standard criteria. Serum creatinine increasing by 2.0 mg/L per day, oliguria, fever, graft swelling, and graft tenderness were considered indications of rejection. In some patients, graft rejection was verified by biopsy. In patients with oliguria or with serum creatinine >30 mgfL in the PredlCya group, the daily dose of Cya was decreased, to avoid Cya nephrotoxicity; patients in whom no improvement of graft function was noted were suspected of allograft rejection. Treatment in such cases was a two-to five-day course of intravenous methylprednisolone (250-1500 mg/ day). All patients were followed up for four to 30 months post-transplant.
Sampling. Blood samples were collected early in the morning, between 0630 and 0800 h, before drug administration. Pre-operative samples were collected after hospitalization but before surgery. When possible, samples were obtained each day throughout the two-week period following transplant, weekly until discharge for about two months, and then monthly or only occasionally thereafter. Plasma or serum specimens were stored at -40 #{176}C until assayed.
Statistical analysis. Student's t-test, paired t-test, and
Fischer's exact probability test were carried out for the data analysis. A value of P <0.05 was considered statistically significant.
Results
Chromatography
Cortisol was satisfactorily recovered from patients' sera, as has also been described in previous papers (23, 24) . Typical chromatograms before and after transplant quantification limit of cortisol was as low as 1 p.g/L and the detection limit, at a signal-to-noise ratio of 3 ± 1, was 0.5 jzgfL. The coefficient of variance (CV) for the quantification limit of cortisol at 1 g/L was 10%. At higher concentrations, e.g., 50 p.g/L, the CV was <3%. The rechromatography of cortisol in the presence of a large amount of methylprednisolone is shown in Figure 2 . The patient in this case had had 1.0 g of methylprednisolone administered intravenously for acute allograft rejection on the previous day. On the first chromatograin, obtained with solvent B, a cortisol peak overlapped that of methylprednisolone. The eluent corresponding to the peak area of cortisol was recovered along with that of dexamethasone as the internal standard. Rechromathgraphy conducted with solvent A led to a satisfactory determination of cortisol. The patients who had been treated repeatedly with high doses of intravenous methylprednisolone within three months after transplant showed cortisol concentrations equal to or below the quantification limit. A total of 14 patients occasionally showed cortisol concentrations <1 g/L after high-dose steroid therapy.
Differences in the cortisol concentrations in serum and plasma were not significant. In most cases, we used serum samples rather than plasma because RFF during repeated analytical runs took longer. Within-run and day-to-day CV in our method was within <2.5%.
We studied interference of cortisol determination by co-administered drugs. Fred and methylprednisolone did not interfere with the peak for cortisol, as mentioned above. Cya, though extracted quantitatively (25) , showed no ultraviolet absorption at 245 nm and thus caused no interference. Aza could be only slightly extracted and showed a minor peak at 65 mm when chromatographed with solvent A. Mizoribine was not extracted with our solvent system, 
Endogenous Cortisol in Transplantation
The average serum concentration of cortisol in 34 recipients before transplantation was 145 (SD 87) g/L, which is in the normal range for healthy subjects. After transplantation, the concentration decreased to 5.93 (SD 5.11) gfL within four days. The concentration-time curve for cortisol (Figure 3 Significantly different from relecton patients(P <0.01). Critical cortisol concentrations, as correlated with early acute allograft rejection or rejection episode, were examined within three months after transplantation. Individual cortisol concentrations within the period beginning from the time of a cumulative Fred dose of 300 mg and ending at 700 mg proved useful for predicting rejection. Data between the third and 12th day after transplant were also useful (data not shown).
We used the cortisol concentration of 4 g/L as our criterion for rejection. Of our 34 transplant recipients, 16 (47%) showed individual average cortisol concentrations >4 g/L during the test period. Among these, 11 recipients (69%) had allograft rejection within three months after transplantation, whereas only 3 (17%) of the 18 recipients whose cortisol concentrations were <4 gfL underwent allograft rejection. The data for all test samples in the period are given in Figure 4 ; in Figure 5 the average values for individual patients are compared with their graft outcomes. Cortisol concentrations exceeding the critical value were clearly correlated with the incidence of acute rejection and (or) rejection episode under both Pred/Aza (P <0.01) and PredlCya (P <0.01) treatment regimens. is reversible for at least three weeks after transplant.
Discussion
Even though strongly suppressed, the adrenal cortex continues to function. Cortisol concentrations within this period were significantly correlated with later rejection episodes. Differences in cortisol concentrations between rejection and no-rejection recipients were statistically significant in each case (P <0.01 for a week, P <0.05 for two and three weeks), but none of any subsequently observed differences was significant. Thus, irreversible organ failure of the hypothalamus-pituitary-adrenal axis may occur as soon as a month after transplan- Because acute rejection occurs generally within three months, and especially within one month, after transplant, it is desirable to predict graft outcome at the earliest possible time. We found that there were statistically significant differences in cortisol concentrations between rejection and no-rejection recipients within a period in which the cumulative Fred dosage was 300-700 mg and daily dosage exceeded 30 mg/day. This period corresponds roughly to from three to 12 days after transplant in both immunosuppressive regimens. Using the data obtained within this period, we defined the critical concentration of cortisol as 4 igfL. Patients with higher cortisol concentrations may have greater risk of rejection, so individualized optimization of steroid therapy is recommended.
Patients administered Fred/Cya had received a halfdaily dose of Fred in contrast to patients given FredlAza. The average concentration of suppressed cortisol was a little higher in patients co-administered Cya instead of Aza, but not statistically significantly so. Nevertheless, the difference seemed correlated with changes in serum creatmine concentrations, possibly because of Cya nephrotoxicity. Failure of renal function in Cya-treated patients may lead to increased concentrations of cortisol in serum, owing to a pharmacokinetic decrease in the plasma clearance of cortisol. However, the adrenocortical toxicity of Cya (32) in humans also should be studied. Data on dose-dependent pharmacokinetics (29, 30 ) and on in vitro hyperbolic Fred effects in mixed lymphocyte cultures (10) indicate that the extent of increase in immunosuppression may decrease with an increase in the area under the concentration curve trations in both immunosuppressive regimens were essentially the same. According to Frey et al. (10) , doses of Fred exceeding 50 mg/day may little enhance its therapeutic value.
Another significant finding of this study is that a cortisol concentration <1 tg/L was elsewhere correlated with severe lung infections (21) . The pharmacokinetics of Pred have been studied in relation to its adverse effects including virus infection (19, 20, 26) . However, Ost et al. (20) stated that the predictive value of Fred kinetics is probably small in routine clinical work because a significant relationship between plasma concentration and effect has yet to be demonstrated. In the present study, cortisol concentrations on some occasions were strongly suppressed to less than the critical value after repeated administrations of high doses of methylprednisolone (33) . The therapeutic efficacy of Fred may thus be reflected in its alternative effect on endogenous cortisol concentrations through the hypothalamus-pituitary-adrenal axis. As discussed above, we saw considerable interindividual differences in endogenous cortisol concentrations among patients whose clinical conditions differed. We could thus predict rejection and lung infection at the earliest possible 
